{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T21:50:18Z","timestamp":1772315418004,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T00:00:00Z","timestamp":1576800000000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Increased numbers of blood and sputum eosinophils are associated with higher exacerbation frequency and increased asthma severity. In clinical trials, targeting Interleukin-5 has been shown to be a useful therapeutic strategy for patients with severe eosinophilic asthma.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Twenty-six patients have been commenced on Reslizumab in our institution since early 2017. Safety and clinical efficacy parameters were recorded at regular intervals.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Mean ACQ-6 score at the start of treatment was 3.5. The average number of exacerbations in the year preceding treatment was 8.3 per person. 30% of patients had been admitted to hospital at least once over the 12\u2009months preceding therapy. 54% of our patients were on long term oral steroid.<\/jats:p>\n<jats:p>Our data showed sustained improvement of Asthma control (Mean improvement in ACQ-6 was 1.7 at 1\u2009year, and 2.0 at 2\u2009years, <jats:italic>P<\/jats:italic>\u2009=\u20090.0001). Of the patients who were on long term systemic steroids, 35.7% discontinued steroids completely, with a mean reduction of prednisolone dose of 5.2\u2009mg at 1\u2009year. There was a 79% reduction in the annual exacerbation frequency at 1\u2009year, and 88% at 2\u2009years (<jats:italic>P<\/jats:italic>\u2009=\u2009&lt;\u20090.0001). Modest, albeit statistically significant increases in creatine kinase which seemed to plateau by 1\u2009year were noted.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Overall, Reslizumab was well tolerated with discontinuation of treatment due to side effects recorded in only one patient. Our data confirm the utility of anti-IL5 therapy in a carefully selected phenotype of severe asthma with evidence of eosinophilic airway inflammation.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12931-019-1251-3","type":"journal-article","created":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T11:02:44Z","timestamp":1576839764000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["The effectiveness of Reslizumab in severe asthma treatment: a real-world experience"],"prefix":"10.1186","volume":"20","author":[{"given":"H.","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"O\u2019Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Casey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"MacSharry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. J.","family":"Plant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. M.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,20]]},"reference":[{"issue":"April 2014","key":"1251_CR1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00202013","volume":"43","author":"KF Chung","year":"2014","unstructured":"Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS \/ ATS guidelines on definition , evaluation and treatment of severe asthma. Eur Respir J. 2014;43(April 2014):343\u201373.","journal-title":"Eur Respir J"},{"key":"1251_CR2","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1183\/13993003.00779-2015","volume":"46","author":"DE Shaw","year":"2015","unstructured":"Shaw DE, Sousa AR, Fowler SJ, Fleming LJ, Roberts G, Corfield J, et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J. 2015;46:1308\u201321.","journal-title":"Eur Respir J"},{"issue":"6","key":"1251_CR3","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jaip.2014.06.005","volume":"2","author":"RS Zeiger","year":"2014","unstructured":"Zeiger RS, Schatz M, Li Q, Chen W, Khatry DB, Gossage D, et al. High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma. J Allergy Clin Immunol Pract. 2014;2(6):741\u201350.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1251_CR4","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S2213-2600(15)00367-7","volume":"3","author":"DB Price","year":"2015","unstructured":"Price DB, Rigazio A, Campbell JD, Bleecker ER, Corrigan CJ, Thomas M, et al. Blood eosinophil count and prospective annual asthma disease burden : a UK cohort study. Lancet Respir. 2015;3:849\u201358.","journal-title":"Lancet Respir"},{"key":"1251_CR5","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1165\/rcmb.2002-0311OC","volume":"30","author":"B Sitkauskiene","year":"2004","unstructured":"Sitkauskiene B, Johansson A, Sergejeva S, Lundin S, Sjo M, Lo J. Regulation of bone marrow and airway CD34+ Eosinophils by Interleukin-5. Am J Respir Cell Mol Biol. 2004;30:367\u201378.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"1251_CR6","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.jaci.2007.03.048","volume":"119","author":"HF Rosenberg","year":"2007","unstructured":"Rosenberg HF, Phipps S, Foster PS. Eosinophil trafficking in allergy and asthma. J Allergy Clin Immunol. 2007;119:1303\u201310.","journal-title":"J Allergy Clin Immunol"},{"issue":"25","key":"1251_CR7","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","volume":"376","author":"P Nair","year":"2017","unstructured":"Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid\u2013sparing effect of Benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448\u201358.","journal-title":"N Engl J Med"},{"issue":"13","key":"1251_CR8","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","volume":"371","author":"HG Ortega","year":"2014","unstructured":"Ortega HG, Liu MC, Pavord ID, Brusselle GG, Fitzgerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe Eosinophilic asthma. N Engl J Med. 2014;371(13):1198\u2013207.","journal-title":"N Engl J Med"},{"issue":"4","key":"1251_CR9","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.chest.2016.03.032","volume":"150","author":"L Bjermer","year":"2016","unstructured":"Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels. Chest. 2016;150(4):789\u201398.","journal-title":"Chest"},{"issue":"4","key":"1251_CR10","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","volume":"150","author":"J Corren","year":"2016","unstructured":"Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 study of Reslizumab in patients with poorly controlled asthma, effects across a broad range of eosinophil counts. Chest. 2016;150(4):799\u2013810.","journal-title":"Chest"},{"issue":"5","key":"1251_CR11","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","volume":"3","author":"M Castro","year":"2015","unstructured":"Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355\u201366.","journal-title":"Lancet Respir Med"},{"issue":"6","key":"1251_CR12","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.jaip.2017.08.024","volume":"5","author":"K Murphy","year":"2017","unstructured":"Murphy K, Jacobs J, Bjermer L, Fahrenholz JM, Shalit Y. Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma. J Allergy Clin Immunol Pract. 2017;5(6):1572\u20131581.e3.","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-019-1251-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12931-019-1251-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-019-1251-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,19]],"date-time":"2020-12-19T00:13:01Z","timestamp":1608336781000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-019-1251-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1251"],"URL":"https:\/\/doi.org\/10.1186\/s12931-019-1251-3","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"16 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Approval was granted to carry out the above study at Cork University Hospitals, approval was granted by the Clinical Research Ethics Committee of the Cork Teaching Hospitals. {CREC Review Reference Number: ECM 4 (e) 25\/07\/2019}.Participants received information pertaining to this study prior to enrollment in the study, the rationale for undertaking the piece of research, study design, participant requirements, potential risks and side effects were explained. All Participants in this study gave their consent prior to being enrolled.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HI, ROS, DC, JM, JMS, BJP report no conflicts of interest. DMM has received both speakers\u2019 fees and fees for advisory boards from Astra Zeneca, GSK, Teva and Novartis. He has travelled to ERS 2018 as a guest of Astra Zeneca.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"289"}}